Medicine, Health & Food

Medicine, Health & Food

Join as an Editor/Reviewer

Association immunohistochemical expression of Programmed Death-Ligand 1 (PD-L1) with degree Tumour Infiltrating Lymphocytes (TILs) as a prognosis factor in clear cell renal cell carcinoma and non clear renal cell carcinoma

Volume: 59  ,  Issue: 1 , August    Published Date: 08 September 2020
Publisher Name: IJRP
Views: 47  ,  Download: 13
DOI: 10.47119/IJRP100591820201379


# Author Name
1 Irmayani
2 Delyuzar
3 Lidya Imelda Laksmi
4 Joko S Lukito
5 Soekimin


Abstract: renal cell carcinoma (RCC) is a cancer originating from renal tubular epithelium and is known as a heterogeneous disease that includes different histological subtypes, CcRCC is the most frequent type and other renal epithelial malignancies as non ccRCC. The expression of PD-L1 in RCC can help to determine the prognosis of RCC patients who are known to be at high risk of having a poor prognosis.To assess the association between immunohistochemical expression of PD-L1 with the degree of TILS in patients with clear cell RCC and non clear RCC. PD-L1 immunohistochemical examination was performed on a fixed slide by using an H-score assessment of 26 samples of RCC and non clear RCC patients. Assessment of the degree of TILs is done on a slide with H&E staining. In our study found that Immunohistochemical expression of PD-L1 was found positive in 20 cases (76.9%) and negative in 6 cases (23.1%). There was no significant association between immunohistochemical expression of PD-L1 with histological types of clear cell RCC and non clear cell RCC. Immunohistochemical expression of PD-L1 is strongly correlated with the degree of TILs, where the higher the degree of PD-L1, the lower the degree of TILs in RCC clear cells and non clear RCC cells. Conclusion: The relationship of immunohistochemical expression of PD-L1 correlates strongly with the degree of TILs, so it can be considered for prognostic examination on RCC and may be considered to be a target therapy for RCC. Keywords: PD-L1, TILs, clear cell RCC, non clear cell RCC, RCC


  • non clear cell RCC
  • clear cell RCC
  • PD-L1
  • RCC
  • TILs
  • References

    1. Moch H, Amin MB, Argani P, Cheville J,  Delahunt B,  Martig G, et al. Renal cell tumour. In: Holger M, Peter A, Thomas M, Victor E, eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs; 4th Ed. 2016. Lyon: IARC. 2016.  pp13-74
    2. Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Giles R.H, et al. Guidelines on renal cell carcinoma. European Association of Urology 2015. pp1-49

    3. Widia F. Clinical predictive factor of metastases in renal cell carcinoma. Fakultas Kedokteran Universitas Indonesia. 2015. pp1-7

    4. Jacquet SF, Deleuze A, Saout J, Mathieu R, Laguerre B, Verhoest G, et al. Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. Int. J. Mol. Sci. 2019, 20. pp1692

    5. Choueiri TK, Fay AP, Gray KP,Callea M, Ho TH, Albiges L, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Annals of Oncology 2015. pp2178–84

    6. Kythreotou A, Siddique A, Mauri AF, Bower M, & Pinato DJ. PD-L1. J Clin Pathol. 2017. pp1-6

    7. Francisco ML, Sage TP & Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews 2010. Vol. 236. pp219–42

    8. Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y. et al. PD-L1 Expression in Clear  Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of  Metastases. 2014; 5(3). pp166-72

    9. Sholl LM, Asiner DL, Allen TC, Beasley MB, Borczuk AC, Cagle PT, et al. Programmed death ligand-1 immunohistochemistry- a new challenge for pathologists.  Arch Pathol Lab Med. 2016; 140. pp341-44

    10. Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, et al. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Cancer Immunol Res; 2015. pp1–5.

    11. Melisa J, Monoarfa A & Tjandra A. Profil penderita karsinoma sel ginjal  (renal cell carcinoma) di RSUP Prof. Dr. R. D. Kandou Manado periode 2013-2015. Jurnal e-Clinic (eCl). 2016. Volume 4, Nomor 2.pp1-6

    12. NguyenDP, Vertosick EA, Corradi RB, Vilaseca A, Benfante NE, Touijer KA, et al.Histological subtype of renal cell carcinoma significantly affects survivalin the era of partial nephrectomy. Urologic Oncol. 2016; 34. pp1-7

    13. Dagher J, Delahunt, Rioux-leclercq N, Egevad L, Srigley J R, Coughlin, GSamaratunga, H. Clear cell renal cell carcinoma: Validation of WHO/ISUP grading. Histophatology, 2017. 71 (6). pp918–25

    14. Chandrasekaran D, Sundram S, KAdhiresan N, PAdmavathi R. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. Asian Pac J Cancer Prev, 2019,20 (10). pp2951-57

    15. Kim SH, Park WS, Park EY, Park B, Joo J, Joung JY, et al. The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2,PD-L1, CA9, PSMA,and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.PLoS ONE 12. 2017 (6). pp1-11

    16. El Hachem G, Choueiry C, Al Hajj Obeid W, Chamseddine N. Renal Squamous Cell Carcinoma: Rare and Aggressive Variant of Renal Cancers. Cancer Biol Ther Oncol. 2017. Vol.1 No. 2:6. pp1-4

    17. Xing Y &  Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol 2012. pp4-9

    18. Chen D.S, Irving B.A & Hodi, F.S. Molecular pathways: Next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 2012, 18. pp6580–87

    19. Dillman RO. Lymphocyte therapy of renal cell carcinoma. Expert Rev Anticancer 2005; 5(6). pp1041-51

    20. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean M-CC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes AA, et al. Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: In?uence of Tumor Origin. Clin cancer Res [Internet] 2013 [cited 2013 Jul 11]; 19. pp4079-91

    21. Nakano O, Sato M, Naito Y, Suzuki K. Proliferative activity of intratumoral CD8C T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res [Internet] 2001 [cited 2015 Jan 6]; 61. pp5132-36

    22. Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, Santarlasci V, Serni S, Cosmi L, Maggi L, et al. Frequency of regulatory T cells in peripheral blood and in tumour-in?ltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int [Internet] 2011 [cited 2014 Dec 19]; 107. pp1500-06